STOCK TITAN

[8-K] Calidi Biotherapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Callan JMB Inc. (CJMB) has entered into a $25 million Equity Line of Credit (ELOC) with a single investor. Over an 18-month term, the company may, at its sole discretion, issue Regular Purchase notices of $0.5-$2.0 million per draw at 95 % of the lowest daily VWAP during a defined measurement period (80 % if CJMB is delisted from Nasdaq). An additional Exemption Purchase option allows draws up to $1 million on similar pricing, plus the investor receives bonus shares equal to 10 % of each exemption draw.

To secure the facility CJMB will issue 15,000 commitment shares and cap the investor’s ownership at 4.99 %. Failure to file or have declared effective an S-1 covering resale of the ELOC and commitment shares within the agreed deadlines triggers a 25,000-share penalty for each breach. All sales are exempt from registration under Section 4(a)(2) until the registration statement is effective. The agreement provides flexible, on-demand financing but could create dilution because shares are sold at a discount and additional shares may be issued as penalties or bonuses.

Callan JMB Inc. (CJMB) ha stipulato una linea di credito azionaria (ELOC) da 25 milioni di dollari con un unico investitore. Per un periodo di 18 mesi, la società potrà, a sua esclusiva discrezione, emettere avvisi di acquisto regolari da 0,5 a 2,0 milioni di dollari per ogni prelievo, al 95% del VWAP giornaliero più basso durante un periodo di misurazione definito (80% se CJMB viene esclusa dal Nasdaq). Un'opzione aggiuntiva di acquisto esente consente prelievi fino a 1 milione di dollari a prezzi simili, e l'investitore riceve azioni bonus pari al 10% di ogni prelievo esente.

Per garantire la linea di credito, CJMB emetterà 15.000 azioni di impegno e limiterà la proprietà dell'investitore al 4,99%. Il mancato deposito o la mancata efficacia di un modulo S-1 che copra la rivendita dell'ELOC e delle azioni di impegno entro le scadenze concordate comporta una penalità di 25.000 azioni per ogni violazione. Tutte le vendite sono esenti da registrazione ai sensi della Sezione 4(a)(2) fino a quando la dichiarazione di registrazione non è efficace. L'accordo offre un finanziamento flessibile e su richiesta, ma potrebbe causare diluizione poiché le azioni vengono vendute a sconto e potrebbero essere emesse ulteriori azioni come penalità o bonus.

Callan JMB Inc. (CJMB) ha establecido una línea de crédito de capital (ELOC) por 25 millones de dólares con un único inversor. Durante un plazo de 18 meses, la empresa podrá, a su exclusiva discreción, emitir avisos de compra regulares de 0.5 a 2.0 millones de dólares por cada extracción, al 95% del VWAP diario más bajo durante un período de medición definido (80% si CJMB es excluida de Nasdaq). Una opción adicional de compra exenta permite extracciones de hasta 1 millón de dólares con precios similares, y el inversor recibe acciones adicionales equivalentes al 10% de cada extracción exenta.

Para asegurar la facilidad, CJMB emitirá 15,000 acciones de compromiso y limitará la propiedad del inversor al 4.99%. El incumplimiento en presentar o en que se declare efectivo un formulario S-1 que cubra la reventa del ELOC y las acciones de compromiso dentro de los plazos acordados genera una penalización de 25,000 acciones por cada incumplimiento. Todas las ventas están exentas de registro bajo la Sección 4(a)(2) hasta que la declaración de registro sea efectiva. El acuerdo ofrece financiamiento flexible y bajo demanda, pero podría causar dilución porque las acciones se venden con descuento y podrían emitirse acciones adicionales como penalizaciones o bonificaciones.

Callan JMB Inc. (CJMB)는 단일 투자자와 2,500만 달러 규모의 자본 신용 한도(ELOC) 계약을 체결했습니다. 18개월 기간 동안 회사는 전적으로 재량에 따라 각 인출 시 50만~200만 달러의 정기 매입 통지를 발행할 수 있으며, 이는 정의된 측정 기간 동안 최저 일일 VWAP의 95% 가격(만약 CJMB가 나스닥에서 상장 폐지될 경우 80%)으로 이루어집니다. 추가 면제 매입 옵션은 유사한 가격으로 최대 100만 달러까지 인출할 수 있으며, 투자자는 각 면제 인출액의 10%에 해당하는 보너스 주식을 받습니다.

이 시설을 확보하기 위해 CJMB는 15,000개의 약정 주식을 발행하고 투자자의 소유 지분을 4.99%로 제한합니다. ELOC 및 약정 주식 재판매를 다루는 S-1 등록 서류를 합의된 기한 내에 제출하거나 효력이 발생하지 않을 경우, 위반 건당 25,000주의 벌칙이 부과됩니다. 모든 판매는 등록 명세서가 효력을 발휘할 때까지 섹션 4(a)(2)에 따라 등록이 면제됩니다. 이 계약은 유연하고 요청 시 자금을 조달할 수 있도록 하지만, 주식이 할인된 가격에 판매되고 벌칙이나 보너스로 추가 주식이 발행될 수 있어 희석 효과가 발생할 수 있습니다.

Callan JMB Inc. (CJMB) a conclu une ligne de crédit en actions (ELOC) de 25 millions de dollars avec un investisseur unique. Sur une période de 18 mois, la société peut, à sa seule discrétion, émettre des avis d'achat réguliers de 0,5 à 2,0 millions de dollars par tirage, à 95 % du VWAP journalier le plus bas pendant une période de mesure définie (80 % si CJMB est retirée du Nasdaq). Une option d'achat d'exemption supplémentaire permet des tirages allant jusqu'à 1 million de dollars à des prix similaires, et l'investisseur reçoit des actions bonus équivalentes à 10 % de chaque tirage d'exemption.

Pour garantir la facilité, CJMB émettra 15 000 actions d'engagement et limitera la propriété de l'investisseur à 4,99 %. Le non-dépôt ou la non-entrée en vigueur d'un formulaire S-1 couvrant la revente de l'ELOC et des actions d'engagement dans les délais convenus entraîne une pénalité de 25 000 actions par violation. Toutes les ventes sont exemptées d'enregistrement en vertu de la section 4(a)(2) jusqu'à ce que la déclaration d'enregistrement soit effective. L'accord offre un financement flexible à la demande, mais peut entraîner une dilution car les actions sont vendues avec une décote et des actions supplémentaires peuvent être émises en tant que pénalités ou bonus.

Callan JMB Inc. (CJMB) hat eine Kapitallinienkreditvereinbarung (ELOC) über 25 Millionen US-Dollar mit einem einzelnen Investor abgeschlossen. Über eine Laufzeit von 18 Monaten kann das Unternehmen nach eigenem Ermessen regelmäßige Kaufmitteilungen in Höhe von 0,5 bis 2,0 Millionen US-Dollar pro Abhebung ausgeben, zum 95 % des niedrigsten täglichen VWAP während eines definierten Messzeitraums (80 % falls CJMB von der Nasdaq delistet wird). Eine zusätzliche Ausnahmekaufoption erlaubt Abhebungen bis zu 1 Million US-Dollar zu ähnlichen Konditionen, außerdem erhält der Investor Bonusaktien in Höhe von 10 % jeder Ausnahmemenge.

Zur Sicherung der Einrichtung wird CJMB 15.000 Verpflichtungsaktien ausgeben und den Anteil des Investors auf 4,99 % begrenzen. Das Versäumnis, eine S-1-Anmeldung zur Wiederveräußerung des ELOC und der Verpflichtungsaktien innerhalb der vereinbarten Fristen einzureichen oder wirksam werden zu lassen, löst eine Strafe von 25.000 Aktien pro Verstoß aus. Alle Verkäufe sind gemäß Abschnitt 4(a)(2) bis zum Wirksamwerden der Registrierungserklärung von der Registrierungspflicht befreit. Die Vereinbarung bietet eine flexible, bedarfsorientierte Finanzierung, kann jedoch zu einer Verwässerung führen, da Aktien mit Abschlag verkauft werden und zusätzliche Aktien als Strafen oder Boni ausgegeben werden können.

Positive
  • Access to up to $25 million in flexible, on-demand equity financing, improving liquidity without increasing debt.
  • 4.99 % ownership cap limits control risk from the financing counterparty.
  • No obligation to draw; management can time capital raises based on market conditions.
Negative
  • Shares sold at 5-20 % discount to VWAP, creating immediate dilution and potential downward price pressure.
  • Commitment, bonus and penalty shares increase share count even without cash proceeds.
  • Registration statement deadlines carry 25 k-share penalties, adding execution risk.

Insights

TL;DR: Optional $25 m ELOC boosts liquidity but adds discounted share supply and dilution risk.

The facility gives CJMB rapid access to capital without upfront debt service, helpful for working-capital or growth needs. Pricing at 95 % of VWAP is in line with small-cap PIPE norms, yet still dilutive and potentially pressures the share price, especially if draw frequency is high. The 4.99 % cap prevents a change of control, but commitment, bonus and penalty shares embed additional dilution. Timely filing of the resale S-1 is critical to avoid issuing 25 k penalty shares. Overall, the agreement is neutral-to-slightly positive for liquidity, negative for existing shareholders’ ownership percentage.

TL;DR: Governance safeguards exist, but discounted share issuance raises dilution and market-impact concerns.

The Purchase and Registration Rights agreements use standard reps & warranties and a sub-5 % ownership cap, limiting concentration risk. However, discount mechanics (up to 20 % if Nasdaq listing is lost) and mandatory bonus shares for exemption purchases incentivize repeated draws that may depress trading prices. Penalty-share clauses for late registration create additional downside. Investors should monitor management’s capital planning discipline and registration timeline adherence. Impact classified as neutral; beneficial to solvency but with notable shareholder dilution risk.

Callan JMB Inc. (CJMB) ha stipulato una linea di credito azionaria (ELOC) da 25 milioni di dollari con un unico investitore. Per un periodo di 18 mesi, la società potrà, a sua esclusiva discrezione, emettere avvisi di acquisto regolari da 0,5 a 2,0 milioni di dollari per ogni prelievo, al 95% del VWAP giornaliero più basso durante un periodo di misurazione definito (80% se CJMB viene esclusa dal Nasdaq). Un'opzione aggiuntiva di acquisto esente consente prelievi fino a 1 milione di dollari a prezzi simili, e l'investitore riceve azioni bonus pari al 10% di ogni prelievo esente.

Per garantire la linea di credito, CJMB emetterà 15.000 azioni di impegno e limiterà la proprietà dell'investitore al 4,99%. Il mancato deposito o la mancata efficacia di un modulo S-1 che copra la rivendita dell'ELOC e delle azioni di impegno entro le scadenze concordate comporta una penalità di 25.000 azioni per ogni violazione. Tutte le vendite sono esenti da registrazione ai sensi della Sezione 4(a)(2) fino a quando la dichiarazione di registrazione non è efficace. L'accordo offre un finanziamento flessibile e su richiesta, ma potrebbe causare diluizione poiché le azioni vengono vendute a sconto e potrebbero essere emesse ulteriori azioni come penalità o bonus.

Callan JMB Inc. (CJMB) ha establecido una línea de crédito de capital (ELOC) por 25 millones de dólares con un único inversor. Durante un plazo de 18 meses, la empresa podrá, a su exclusiva discreción, emitir avisos de compra regulares de 0.5 a 2.0 millones de dólares por cada extracción, al 95% del VWAP diario más bajo durante un período de medición definido (80% si CJMB es excluida de Nasdaq). Una opción adicional de compra exenta permite extracciones de hasta 1 millón de dólares con precios similares, y el inversor recibe acciones adicionales equivalentes al 10% de cada extracción exenta.

Para asegurar la facilidad, CJMB emitirá 15,000 acciones de compromiso y limitará la propiedad del inversor al 4.99%. El incumplimiento en presentar o en que se declare efectivo un formulario S-1 que cubra la reventa del ELOC y las acciones de compromiso dentro de los plazos acordados genera una penalización de 25,000 acciones por cada incumplimiento. Todas las ventas están exentas de registro bajo la Sección 4(a)(2) hasta que la declaración de registro sea efectiva. El acuerdo ofrece financiamiento flexible y bajo demanda, pero podría causar dilución porque las acciones se venden con descuento y podrían emitirse acciones adicionales como penalizaciones o bonificaciones.

Callan JMB Inc. (CJMB)는 단일 투자자와 2,500만 달러 규모의 자본 신용 한도(ELOC) 계약을 체결했습니다. 18개월 기간 동안 회사는 전적으로 재량에 따라 각 인출 시 50만~200만 달러의 정기 매입 통지를 발행할 수 있으며, 이는 정의된 측정 기간 동안 최저 일일 VWAP의 95% 가격(만약 CJMB가 나스닥에서 상장 폐지될 경우 80%)으로 이루어집니다. 추가 면제 매입 옵션은 유사한 가격으로 최대 100만 달러까지 인출할 수 있으며, 투자자는 각 면제 인출액의 10%에 해당하는 보너스 주식을 받습니다.

이 시설을 확보하기 위해 CJMB는 15,000개의 약정 주식을 발행하고 투자자의 소유 지분을 4.99%로 제한합니다. ELOC 및 약정 주식 재판매를 다루는 S-1 등록 서류를 합의된 기한 내에 제출하거나 효력이 발생하지 않을 경우, 위반 건당 25,000주의 벌칙이 부과됩니다. 모든 판매는 등록 명세서가 효력을 발휘할 때까지 섹션 4(a)(2)에 따라 등록이 면제됩니다. 이 계약은 유연하고 요청 시 자금을 조달할 수 있도록 하지만, 주식이 할인된 가격에 판매되고 벌칙이나 보너스로 추가 주식이 발행될 수 있어 희석 효과가 발생할 수 있습니다.

Callan JMB Inc. (CJMB) a conclu une ligne de crédit en actions (ELOC) de 25 millions de dollars avec un investisseur unique. Sur une période de 18 mois, la société peut, à sa seule discrétion, émettre des avis d'achat réguliers de 0,5 à 2,0 millions de dollars par tirage, à 95 % du VWAP journalier le plus bas pendant une période de mesure définie (80 % si CJMB est retirée du Nasdaq). Une option d'achat d'exemption supplémentaire permet des tirages allant jusqu'à 1 million de dollars à des prix similaires, et l'investisseur reçoit des actions bonus équivalentes à 10 % de chaque tirage d'exemption.

Pour garantir la facilité, CJMB émettra 15 000 actions d'engagement et limitera la propriété de l'investisseur à 4,99 %. Le non-dépôt ou la non-entrée en vigueur d'un formulaire S-1 couvrant la revente de l'ELOC et des actions d'engagement dans les délais convenus entraîne une pénalité de 25 000 actions par violation. Toutes les ventes sont exemptées d'enregistrement en vertu de la section 4(a)(2) jusqu'à ce que la déclaration d'enregistrement soit effective. L'accord offre un financement flexible à la demande, mais peut entraîner une dilution car les actions sont vendues avec une décote et des actions supplémentaires peuvent être émises en tant que pénalités ou bonus.

Callan JMB Inc. (CJMB) hat eine Kapitallinienkreditvereinbarung (ELOC) über 25 Millionen US-Dollar mit einem einzelnen Investor abgeschlossen. Über eine Laufzeit von 18 Monaten kann das Unternehmen nach eigenem Ermessen regelmäßige Kaufmitteilungen in Höhe von 0,5 bis 2,0 Millionen US-Dollar pro Abhebung ausgeben, zum 95 % des niedrigsten täglichen VWAP während eines definierten Messzeitraums (80 % falls CJMB von der Nasdaq delistet wird). Eine zusätzliche Ausnahmekaufoption erlaubt Abhebungen bis zu 1 Million US-Dollar zu ähnlichen Konditionen, außerdem erhält der Investor Bonusaktien in Höhe von 10 % jeder Ausnahmemenge.

Zur Sicherung der Einrichtung wird CJMB 15.000 Verpflichtungsaktien ausgeben und den Anteil des Investors auf 4,99 % begrenzen. Das Versäumnis, eine S-1-Anmeldung zur Wiederveräußerung des ELOC und der Verpflichtungsaktien innerhalb der vereinbarten Fristen einzureichen oder wirksam werden zu lassen, löst eine Strafe von 25.000 Aktien pro Verstoß aus. Alle Verkäufe sind gemäß Abschnitt 4(a)(2) bis zum Wirksamwerden der Registrierungserklärung von der Registrierungspflicht befreit. Die Vereinbarung bietet eine flexible, bedarfsorientierte Finanzierung, kann jedoch zu einer Verwässerung führen, da Aktien mit Abschlag verkauft werden und zusätzliche Aktien als Strafen oder Boni ausgegeben werden können.

false 0001855485 0001855485 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2025

 

Calidi Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40789   86-2967193

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

4475 Executive Dr., Suite 200,

San Diego, CA

  92121
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 794-9600

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class   Trading Symbol   Name of each exchange on which registered
         
Common stock, par value $0.0001 per share   CLDI   NYSE American LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 24, 2025, the Compensation Committee of Calidi Biotherapeutics, Inc. (the “Company”) approved the elimination of the position of President, Medical and Scientific Affairs (the “Position”), held by Dr. Boris Minev (the “Executive”). As a result, the Executive will cease to serve as an executive officer and a Section 16 officer of the Company, effective July 29, 2025. The Company expects to enter into a Separation and General Release of Claims Agreement with Dr. Minev, and, to the extent any such agreement is entered into, the Company will file a Current Report on Form 8-K disclosing the material terms of such arrangement.

 

The Position has been eliminated as part of the Company’s ongoing review of its organizational structure and cost optimization efforts and not as a result of any disagreement between Dr. Minev and the Company or its board of directors or any matter relating to the Company’s operations, policies, or practices. Dr. Guy Travis Clifton, the Company’s Chief Medical Officer, Consultant and Advisor, will assume Dr. Minev’s responsibilities.

 

Item 7.01 Regulation FD Disclosure

 

On July 25, 2025, Calidi Biotherapeutics, Inc., (the “Company”) issued a press release announcing a proposed reverse stock split of its common stock at a ratio of 1-for-12. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information reported under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, is being “furnished” and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

 

Item 8.01 Other Events

 

On July 25, 2025, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit   Exhibit Description
99.1   Press Release dated July 25, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Calidi Biotherapeutics, Inc.
Dated: July 25, 2025    
  By: /s/ Andrew Jackson
  Name: Andrew Jackson
  Title: Chief Financial Officer

 

 

 

FAQ

How much capital can Callan JMB (CJMB) raise under the new ELOC?

The company may sell up to $25 million of common stock to the investor over an 18-month term.

At what price will CJMB shares be sold to the investor?

Regular and exemption purchases are priced at 95 % of the lowest daily VWAP in the measurement period (80 % if delisted).

What dilution protections exist for existing CJMB shareholders?

The investor’s stake is capped at 4.99 %, but discounted pricing and bonus shares still dilute current holders.

What happens if CJMB misses the registration filing deadline?

The company must issue an additional 25,000 shares to the investor if it fails to file or make effective the registration statement on time.

Is CJMB obligated to use the ELOC?

No. Management decides whether and when to issue purchase notices; the facility is purely discretionary.
Calidi Biotherapeutics Inc

NYSE:CLDI

CLDI Rankings

CLDI Latest News

CLDI Latest SEC Filings

CLDI Stock Data

25.52M
34.45M
7.88%
4.06%
2.99%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO